

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Keith BIGGADIKE et al.

Serial No.: 10/564,299

Art Unit: 1614

Filing Date: September 12, 2006

Examiner: To be assigned

For: *Specific Glucocorticosteroid Compounds
Having Anti-Inflammatory Activity*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



James F. Riek
Attorney of Record
Registration No. 39,009

Date: 6-11-2007
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

FORM PTO-1449				SERIAL NO.		10/564,299	
INFORMATION DISCLOSURE STATEMENT				FILING DATE		September 12, 2006	
				APPLICANT		Keith Biggadike et al.	
				GROUP		1614	
				EXAMINER		To be assigned	
				ATTORNEY DOCKET NO.		PB60925USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	5,552,438	09/03/1996	CHRISTENSEN, IV			
	2.	6,172,054	01/09/2001	CLARK			
	3.	6,245,804	06/12/2001	LEHMANN et al.			
	4.	6,395,738	05/28/2002	OHSHIMA et al.			
	5.	6,897,224	05/24/2005	JAROCK et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	6.	GB 1384372	02/19/1975	GB			
	7.	GB 2079755	01/27/1982	GB			
	8.	GB 2137206	10/03/1984	GB			
	9.	WO 89/03390	04/20/1989	PCT			
	10.	WO 93/13055	07/08/1993	PCT			
	11.	WO 95/34534	12/21/1995	PCT			
	12.	WO 97/41867	11/13/1997	PCT			
	13.	WO 98/30537	07/16/1998	PCT			
	14.	WO 98/54159	12/03/1998	PCT			
	15.	WO 99/16766	04/08/1999	PCT			X
	16.	WO 99/32127	07/01/1999	PCT			X
	17.	WO 99/47505	09/23/1999	PCT			
	18.	WO 99/62875	12/09/1999	PCT			
	19.	WO 00/66590	11/09/2000	PCT			
	20.	WO 01/04118	01/18/2001	PCT			
	21.	WO 01/10143	02/08/2001	PCT			
	22.	WO 01/16128	03/08/2001	PCT			
	23.	WO 01/42193	06/14/2001	PCT			
	24.	WO 02/02565	01/10/2002	PCT			
	25.	WO 02/26722	04/04/2002	PCT			
	26.	WO 02/40030	05/23/2002	PCT			
	27.	WO 02/50021	06/27/2002	PCT			
	28.	WO 02/66422	08/29/2002	PCT			
	29.	WO 02/70490	09/12/2002	PCT			
	30.	WO 02/76933	10/03/2002	PCT			
	31.	WO 03/08277	01/30/2003	PCT			
	32.	WO 03/024439	03/27/2003	PCT			
	33.	WO 03/042160	05/23/2003	PCT			
	34.	WO 03/059899	07/24/2003	PCT			
Continue on page 2							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/564,299	
				FILING DATE		September 12, 2006	
				APPLICANT		Keith Biggadike et al.	
				GROUP		1614	
				EXAMINER		To be assigned	
				ATTORNEY DOCKET NO.		PB60925USw	
FOREIGN PATENT DOCUMENTS (Cont'd)							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	35.	WO 03/061651	07/31/2003	PCT			
	36.	WO 03/072539	09/04/2003	PCT			
	37.	WO 03/082280	10/09/2003	PCT			
	38.	WO 03/082787	10/09/2003	PCT			
	39.	WO 03/082827	10/09/2003	PCT			X
	40.	WO 03/086294	10/23/2003	PCT			
	41.	WO 03/091204	11/06/2003	PCT			
	42.	WO 03/101932	12/11/2003	PCT			
	43.	WO 03/104195	12/18/2003	PCT			
	44.	WO 04/005229	01/15/2004	PCT			
	45.	WO 04/009016	01/29/2004	PCT			
	46.	WO 04/009017	01/29/2004	PCT			
	47.	WO 04/016578	02/26/2004	PCT			
	48.	WO 04/018429	03/04/2004	PCT			
	49.	WO 04/022547	03/18/2004	PCT			
	50.	WO 04/024728	03/25/2004	PCT			
	51.	WO 04/026248	04/01/2004	PCT			
	52.	WO 04/037768	05/06/2004	PCT			
	53.	WO 04/037773	05/06/2004	PCT			
	54.	WO 04/037807	05/06/2004	PCT			
	55.	WO 04/039762	05/13/2004	PCT			
	56.	WO 04/039766	05/13/2004	PCT			
	57.	WO 04/056823	07/08/2004	PCT			
	58.	WO 04/103998	12/02/2004	PCT			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	59.	Austin et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," <i>Eur Resp J</i> 20(6):1386-1392 (Dec. 2002).					
	60.	Fuji et al., "Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen," <i>J Pharmacol Exp Ther</i> 284(1):162 (1998).					
	61.	Landells et al., "Oral administration of the phosphodiesterase (PDE)4 inhibitor, VI1294A inhibits ex-vivo agonist-induced-cell activation," <i>Eur Resp J (Ann Cong Eur Resp Soc, Geneva)</i> 12(Suppl. 28) Abst P2393 (Sep. 1998).					
	62.	RACHWAL et al., "Chemistry of luteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds," <i>Steroids</i> 63 (4):193-201 (1998)					
	63.	Ray et al., "Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor γ , and inhibition by glucocorticoids," <i>Biochem J</i> 328:707-715 (Dec. 1997).					
	64.	Phillips, GH et al., "Synthesis and structure activity Relationships in a series of Anti-inflammatory Corticosteroid Analogues, Halomethyl Androstane - 17B-carbothioates and -17B-carboselenoates," <i>Journal of Medicinal Chemistry</i> 1994, 37, 3717-3729.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							